These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 31187938)

  • 1. Improved oral bioavailability of repaglinide, a typical BCS Class II drug, with a chitosan-coated nanoemulsion.
    Karami Z; Saghatchi Zanjani MR; Nasihatsheno N; Hamidi M
    J Biomed Mater Res B Appl Biomater; 2020 Apr; 108(3):717-728. PubMed ID: 31187938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparation of nanoparticle and nanoemulsion formulations containing repaglinide and determination of pharmacokinetic parameters in rats.
    Demirturk E; Ugur Kaplan AB; Cetin M; Dönmez Kutlu M; Köse S; Akıllıoğlu K
    Eur J Pharm Sci; 2024 Sep; 200():106844. PubMed ID: 38977205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoemulsion: for improved oral delivery of repaglinide.
    Akhtar J; Siddiqui HH; Fareed S; Badruddeen ; Khalid M; Aqil M
    Drug Deliv; 2016 Jul; 23(6):2026-34. PubMed ID: 27187792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparation, Characterization and In Vivo Assessment of Repaglinide Nanosuspension for Oral Bioavailability Improvement.
    Zawar LR; Bari SB
    Recent Pat Drug Deliv Formul; 2018; 12(3):162-169. PubMed ID: 30003863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preparation, characterization and in vivo evaluation of formulation of repaglinide with hydroxypropyl-β-cyclodextrin.
    Liu M; Cao W; Sun Y; He Z
    Int J Pharm; 2014 Dec; 477(1-2):159-66. PubMed ID: 25455768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and Development of Repaglinide Microemulsion Gel for Transdermal Delivery.
    Shinde UA; Modani SH; Singh KH
    AAPS PharmSciTech; 2018 Jan; 19(1):315-325. PubMed ID: 28717973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repaglinide-loaded long-circulating biodegradable nanoparticles: rational approach for the management of type 2 diabetes mellitus.
    Jain S; Saraf S
    J Diabetes; 2009 Mar; 1(1):29-35. PubMed ID: 20923517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Impact of Surfactant Composition and Surface Charge of Niosomes on the Oral Absorption of Repaglinide as a BCS II Model Drug.
    Yaghoobian M; Haeri A; Bolourchian N; Shahhosseni S; Dadashzadeh S
    Int J Nanomedicine; 2020; 15():8767-8781. PubMed ID: 33204087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and characterization of a novel lipohydrogel nanocarrier: repaglinide as a lipophilic model drug.
    Ebrahimi HA; Javadzadeh Y; Hamidi M; Barzegar Jalali M
    J Pharm Pharmacol; 2016 Apr; 68(4):450-8. PubMed ID: 27114047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanoemulsions coated with alginate/chitosan as oral insulin delivery systems: preparation, characterization, and hypoglycemic effect in rats.
    Li X; Qi J; Xie Y; Zhang X; Hu S; Xu Y; Lu Y; Wu W
    Int J Nanomedicine; 2013; 8():23-32. PubMed ID: 23293517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A study on ethosomes as mode for transdermal delivery of an antidiabetic drug.
    Bodade SS; Shaikh KS; Kamble MS; Chaudhari PD
    Drug Deliv; 2013; 20(1):40-6. PubMed ID: 23311652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of nifedipine on the pharmacokinetics of repaglinide in rats: possible role of CYP3A4 and P-glycoprotein inhibition by nifedipine.
    Choi JS; Choi I; Choi DH
    Pharmacol Rep; 2013; 65(5):1422-30. PubMed ID: 24399740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chitosan nanoparticles/cellulose nanocrystals nanocomposites as a carrier system for the controlled release of repaglinide.
    Abo-Elseoud WS; Hassan ML; Sabaa MW; Basha M; Hassan EA; Fadel SM
    Int J Biol Macromol; 2018 May; 111():604-613. PubMed ID: 29325745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Porous carrier based floating granular delivery system of repaglinide.
    Jain SK; Agrawal GP; Jain NK
    Drug Dev Ind Pharm; 2007 Apr; 33(4):381-91. PubMed ID: 17523003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and evaluation of self-nanoemulsifying pellets of repaglinide.
    Desai NS; Nagarsenker MS
    AAPS PharmSciTech; 2013 Sep; 14(3):994-1003. PubMed ID: 23775389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fast dissolving electrospun polymeric films of anti-diabetic drug repaglinide: formulation and evaluation.
    Thakkar S; More N; Sharma D; Kapusetti G; Kalia K; Misra M
    Drug Dev Ind Pharm; 2019 Dec; 45(12):1921-1930. PubMed ID: 31625774
    [No Abstract]   [Full Text] [Related]  

  • 17. Biocompatible nanoemulsions based on hemp oil and less surfactants for oral delivery of baicalein with enhanced bioavailability.
    Yin J; Xiang C; Wang P; Yin Y; Hou Y
    Int J Nanomedicine; 2017; 12():2923-2931. PubMed ID: 28435268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanosuspension-Based Repaglinide Fast-Dissolving Buccal Film for Dissolution Enhancement.
    Ghadhban HY; Ahmed KK
    AAPS PharmSciTech; 2024 Jul; 25(6):161. PubMed ID: 38992175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of lipid matrix on repaglinide-loaded solid lipid nanoparticles for oral delivery.
    Rawat MK; Jain A; Mishra A; Muthu MS; Singh S
    Ther Deliv; 2010 Jul; 1(1):63-73. PubMed ID: 22816120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arteether nanoemulsion for enhanced efficacy against Plasmodium yoelii nigeriensis malaria: an approach by enhanced bioavailability.
    Dwivedi P; Khatik R; Chaturvedi P; Khandelwal K; Taneja I; Raju KS; Dwivedi H; Singh SK; Gupta PK; Shukla P; Tripathi P; Singh S; Tripathi R; Wahajuddin ; Paliwal SK; Dwivedi AK; Mishra PR
    Colloids Surf B Biointerfaces; 2015 Feb; 126():467-75. PubMed ID: 25616971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.